Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAS41008 versus Fumaderm and placebo in moderate to severe chronic plaque psoriasis
NL-OMON39748Phase 3Active, not recruiting
- Sponsor
- Almirall
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dimethyl fumarate, Fumaderm and Placebo-COD Research Private Ltd in psoriasis and plaque psoriasis, sponsored by Almirall. Started Oct 2013; status: active, not recruiting.
02
Drugs
dimethyl fumarateFumadermPlacebo-COD Research Private Ltd
03
Conditions
psoriasisplaque psoriasis
Beyond the preview
Go deeper on NL-OMON39748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39748.